

# Zhan Ju Liu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2550855/publications.pdf>

Version: 2024-02-01

67  
papers

5,212  
citations

136740  
32  
h-index

95083  
68  
g-index

68  
all docs

68  
docs citations

68  
times ranked

7620  
citing authors

#	ARTICLE	IF	CITATIONS
1	Microbiota metabolite short chain fatty acids, GPCR, and inflammatory bowel diseases. <i>Journal of Gastroenterology</i> , 2017, 52, 1-8.	2.3	632
2	Clinical Features of COVID-19-Related Liver Functional Abnormality. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1561-1566.	2.4	628
3	Intestinal microbiota-derived short-chain fatty acids regulation of immune cell IL-22 production and gut immunity. <i>Nature Communications</i> , 2020, 11, 4457.	5.8	480
4	Microbiota-derived short-chain fatty acids promote Th1 cell IL-10 production to maintain intestinal homeostasis. <i>Nature Communications</i> , 2018, 9, 3555.	5.8	380
5	GPR43 mediates microbiota metabolite SCFA regulation of antimicrobial peptide expression in intestinal epithelial cells via activation of mTOR and STAT3. <i>Mucosal Immunology</i> , 2018, 11, 752-762.	2.7	322
6	CD177 <sup>+</sup> neutrophils as functionally activated neutrophils negatively regulate IBD. <i>Gut</i> , 2018, 67, 1052-1063.	6.1	159
7	miR-10a inhibits dendritic cell activation and Th1/Th17 cell immune responses in IBD. <i>Gut</i> , 2015, 64, 1755-1764.	6.1	143
8	MicroRNA-31 Reduces Inflammatory Signaling and Promotes Regeneration in Colon Epithelium, and Delivery of Mimics in Microspheres Reduces Colitis in Mice. <i>Gastroenterology</i> , 2019, 156, 2281-2296.e6.	0.6	140
9	Microbiota metabolite butyrate constrains neutrophil functions and ameliorates mucosal inflammation in inflammatory bowel disease. <i>Gut Microbes</i> , 2021, 13, 1968257.	4.3	138
10	miR-301a promotes intestinal mucosal inflammation through induction of IL-17A and TNF- $\alpha$ in IBD. <i>Gut</i> , 2016, 65, 1938-1950.	6.1	137
11	Potential roles of neutrophils in regulating intestinal mucosal inflammation of inflammatory bowel disease. <i>Journal of Digestive Diseases</i> , 2017, 18, 495-503.	0.7	136
12	Prevention of Experimental Colitis in SCID Mice Reconstituted with CD45RB <sup>high</sup> CD4 <sup>+</sup> T Cells by Blocking the CD40-CD154 Interactions. <i>Journal of Immunology</i> , 2000, 164, 6005-6014.	0.4	118
13	MicroRNA 301A Promotes Intestinal Inflammation and Colitis-Associated Cancer Development by Inhibiting BTG1. <i>Gastroenterology</i> , 2017, 152, 1434-1448.e15.	0.6	118
14	The increased expression of IL-23 in inflammatory bowel disease promotes intraepithelial and lamina propria lymphocyte inflammatory responses and cytotoxicity. <i>Journal of Leukocyte Biology</i> , 2011, 89, 597-606.	1.5	113
15	Microbiota Metabolite Butyrate Differentially Regulates Th1 and Th17 Cells <sup>TM</sup> Differentiation and Function in Induction of Colitis. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1450-1461.	0.9	112
16	IL-25 Downregulates Th1/Th17 Immune Response in an IL-10-Dependent Manner in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 720-728.	0.9	86
17	IL-21 enhances NK cell activation and cytolytic activity and induces Th17 cell differentiation in inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 1133-1144.	0.9	75
18	ATF4 Deficiency Promotes Intestinal Inflammation in Mice by Reducing Uptake of Glutamine and Expression of Antimicrobial Peptides. <i>Gastroenterology</i> , 2019, 156, 1098-1111.	0.6	67

#	ARTICLE	IF	CITATIONS
19	ASCA, ANCA, ALCA and Many More: Are They Useful in the Diagnosis of Inflammatory Bowel Disease?. Digestive Diseases, 2016, 34, 90-97.	0.8	56
20	CD177+ neutrophils suppress epithelial cell tumourigenesis in colitis-associated cancer and predict good prognosis in colorectal cancer. Carcinogenesis, 2018, 39, 272-282.	1.3	54
21	Anti-TNF- $\alpha$ Therapy Suppresses Proinflammatory Activities of Mucosal Neutrophils in Inflammatory Bowel Disease. Mediators of Inflammation, 2018, 2018, 1-12.	1.4	49
22	Microbial and metabolic features associated with outcome of infliximab therapy in pediatric Crohn's disease. Gut Microbes, 2021, 13, 1-18.	4.3	47
23	Serum Levels of Lipopolysaccharide and 1,3- $\beta$ -D-Glucan Refer to the Severity in Patients with Crohn's Disease. Mediators of Inflammation, 2015, 2015, 1-9.	1.4	46
24	Tripartite motif-containing (TRIM) 21 negatively regulates intestinal mucosal inflammation through inhibiting TH1/TH17 cell differentiation in patients with inflammatory bowel diseases. Journal of Allergy and Clinical Immunology, 2018, 142, 1218-1228.e12.	1.5	46
25	Microbiota Metabolite Short-Chain Fatty Acids Facilitate Mucosal Adjuvant Activity of Cholera Toxin through GPR43. Journal of Immunology, 2019, 203, 282-292.	0.4	46
26	Microbiota regulation of inflammatory bowel disease and colorectal cancer. Seminars in Cancer Biology, 2013, 23, 543-552.	4.3	45
27	MicroRNA-125a suppresses intestinal mucosal inflammation through targeting ETS-1 in patients with inflammatory bowel diseases. Journal of Autoimmunity, 2019, 101, 109-120.	3.0	44
28	Blockage of tumor necrosis factor prevents intestinal mucosal inflammation through down-regulation of interleukin-23 secretion. Journal of Autoimmunity, 2007, 29, 187-194.	3.0	42
29	Clinical significance of soluble immunoglobulins A and G and their coated bacteria in feces of patients with inflammatory bowel disease. Journal of Translational Medicine, 2018, 16, 359.	1.8	42
30	Interleukin (IL)-23 Suppresses IL-10 in Inflammatory Bowel Disease. Journal of Biological Chemistry, 2012, 287, 3591-3597.	1.6	41
31	Anti-TNF Therapy Induces CD4+ T-Cell Production of IL-22 and Promotes Epithelial Repairs in Patients With Crohn's Disease. Inflammatory Bowel Diseases, 2018, 24, 1733-1744.	0.9	39
32	Critical roles of bile acids in regulating intestinal mucosal immune responses. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110180.	1.4	38
33	Microbiota-specific Th17 Cells. Inflammatory Bowel Diseases, 2016, 22, 1473-1482.	0.9	36
34	Cyclosporine modulates neutrophil functions via the SIRT6-HIF1 $\alpha$ glycolysis axis to alleviate severe ulcerative colitis. Clinical and Translational Medicine, 2021, 11, e334.	1.7	36
35	Neutrophils Promote Amphiregulin Production in Intestinal Epithelial Cells through TGF- $\beta$ 2 and Contribute to Intestinal Homeostasis. Journal of Immunology, 2018, 201, 2492-2501.	0.4	34
36	Critical role of ROCK2 activity in facilitating mucosal CD4 + T cell activation in inflammatory bowel disease. Journal of Autoimmunity, 2018, 89, 125-138.	3.0	33

#	ARTICLE	IF	CITATIONS
37	Critical Role of CD6highCD4+ T Cells in Driving Th1/Th17 Cell Immune Responses and Mucosal Inflammation in IBD. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 510-524.	0.6	31
38	TRIM21 Is Decreased in Colitis-associated Cancer and Negatively Regulates Epithelial Carcinogenesis. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 458-468.	0.9	30
39	Current diagnosis and management of Crohn's disease in China: results from a multicenter prospective disease registry. <i>BMC Gastroenterology</i> , 2019, 19, 145.	0.8	29
40	Small heat shock protein CRYAB inhibits intestinal mucosal inflammatory responses and protects barrier integrity through suppressing IKK $\beta$ activity. <i>Mucosal Immunology</i> , 2019, 12, 1291-1303.	2.7	29
41	Divalent metal-ion transporter 1 is decreased in intestinal epithelial cells and contributes to the anemia in inflammatory bowel disease. <i>Scientific Reports</i> , 2015, 5, 16344.	1.6	23
42	Changes of immunocytic phenotypes and functions from human colorectal adenomatous stage to cancerous stage: Update. <i>Immunobiology</i> , 2015, 220, 1186-1196.	0.8	23
43	ROR $\gamma$ t Represses IL-10 Production in Th17 Cells To Maintain Their Pathogenicity in Inducing Intestinal Inflammation. <i>Journal of Immunology</i> , 2019, 202, 79-92.	0.4	23
44	Dichotomous roles of neutrophils in modulating pathogenic and repair processes of inflammatory bowel diseases. <i>Precision Clinical Medicine</i> , 2021, 4, 246-257.	1.3	20
45	Infliximab Preferentially Induces Clinical Remission and Mucosal Healing in Short Course Crohn's Disease with Luminal Lesions through Balancing Abnormal Immune Response in Gut Mucosa. <i>Mediators of Inflammation</i> , 2015, 2015, 1-9.	1.4	19
46	CD99 refers to the activity of inflammatory bowel disease. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 359-364.	0.6	19
47	Validation in China of a non-invasive salivary pepsin biomarker containing two unique human pepsin monoclonal antibodies to diagnose gastroesophageal reflux disease. <i>Journal of Digestive Diseases</i> , 2019, 20, 278-287.	0.7	17
48	Anti-TNF- $\alpha$ Monoclonal Antibody Therapy Improves Anemia through Downregulating Hepatocyte Hcpidin Expression in Inflammatory Bowel Disease. <i>Mediators of Inflammation</i> , 2019, 2019, 1-13.	1.4	17
49	Efficacy and safety of adalimumab in Chinese patients with moderately to severely active Crohn's disease: results from a randomized trial. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482093896.	1.4	16
50	Interplay of intestinal microbiota and mucosal immunity in inflammatory bowel disease: a relationship of frenemies. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482093518.	1.4	16
51	GPR65 promotes intestinal mucosal Th1 and Th17 cell differentiation and gut inflammation through downregulating NUA2. <i>Clinical and Translational Medicine</i> , 2022, 12, e771.	1.7	15
52	Blockade of PLD2 Ameliorates Intestinal Mucosal Inflammation of Inflammatory Bowel Disease. <i>Mediators of Inflammation</i> , 2016, 2016, 1-14.	1.4	14
53	Twist1 contributes to developing and sustaining corticosteroid resistance in ulcerative colitis. <i>Theranostics</i> , 2021, 11, 7797-7812.	4.6	13
54	Natural Herbal Remedy Wumei Decoction Ameliorates Intestinal Mucosal Inflammation by Inhibiting Th1/Th17 Cell Differentiation and Maintaining Microbial Homeostasis. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1061-1071.	0.9	12

#	ARTICLE	IF	CITATIONS
55	Monocyte Chemotactic Protein 1-Induced Protein 1 Is Highly Expressed in Inflammatory Bowel Disease and Negatively Regulates Neutrophil Activities. <i>Mediators of Inflammation</i> , 2020, 2020, 1-15.	1.4	11
56	Hyperamylasemia, Reactive Plasmacytosis, and Immune Abnormalities in a Patient with Celiac Disease. <i>Digestive Diseases and Sciences</i> , 2007, 52, 1444-1447.	1.1	9
57	Macrophage-derived EDA-A2 inhibits intestinal stem cells by targeting miR-494/EDA2R/ $\beta^2$ -catenin signaling in mice. <i>Communications Biology</i> , 2021, 4, 213.	2.0	9
58	TNFAIP3 Facilitates Degradation of Microbial Antigen SEB in Enterocytes. <i>PLoS ONE</i> , 2012, 7, e45941.	1.1	8
59	Serum bacterial toxins are related to the progression of inflammatory bowel disease. <i>Scandinavian Journal of Gastroenterology</i> , 2014, 49, 826-833.	0.6	8
60	Association of Serum Immunoglobulins Levels With Specific Disease Phenotypes of Crohn's Disease: A Multicenter Analysis in China. <i>Frontiers in Medicine</i> , 2021, 8, 621337.	1.2	8
61	The Degree of Ulcerative Colitis Burden of Luminal Inflammation score is superior to predicting medium- to long-term prognosis in patients with active ulcerative colitis. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482098121.	1.4	8
62	Clinicopathological and Ileocolonoscopy Characteristics in Patients with Nodular Lymphoid Hyperplasia in the Terminal Ileum. <i>International Journal of Medical Sciences</i> , 2017, 14, 750-757.	1.1	7
63	TOB1 Blocks Intestinal Mucosal Inflammation Through Inducing ID2-Mediated Suppression of Th1/Th17 Cell Immune Responses in IBD. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2022, 13, 1201-1221.	2.3	6
64	Risks of Cardiovascular Events in Patients With Inflammatory Bowel Disease in China: A Retrospective Multicenter Cohort Study. <i>Inflammatory Bowel Diseases</i> , 2022, 28, S52-S58.	0.9	6
65	MicroRNA-10a Negatively Regulates CD4+ T Cell IL-10 Production through Suppression of Blimp1. <i>Journal of Immunology</i> , 2021, 207, 985-995.	0.4	4
66	The Development and Validation of Anti-paratuberculosis-nocardia Polypeptide Antibody [Anti-pTNP] for the Diagnosis of Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2022, , .	0.6	2
67	Anti-TNF and immunosuppressive combination therapy is preferential to inducing clinical remission in patients with active inflammatory bowel disease: A systemic review and meta-analysis. <i>Journal of Digestive Diseases</i> , 2021, 22, 408-418.	0.7	1